Evidence map›Paper›PMID 35869099›Full record

ArticleScientific reports2022

A comparison of high-throughput SARS-CoV-2 sequencing methods from nasopharyngeal samples.

Zuzana Gerber, Christian Daviaud, Damien Delafoy, Florian Sandron, Enagnon Kazali Alidjinou, Jonathan Mercier, Sylvain Gerber, Vincent Meyer, Anne Boland, Laurence Bocket and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Enrichment techniques for clinical metagenomics.Frontiers in cellular and infection microbiology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A comparison of five Illumina, Ion Torrent, and nanopore sequencing technology-based approaches for whole genome sequencing of SARS-CoV-2.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Zuzana GerberCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France. gerber@cnrgh.fr.
Christian DaviaudCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
Damien DelafoyCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
Florian SandronCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
Enagnon Kazali AlidjinouLaboratoire de Virologie ULR 3610, CHU Lille, University of Lille, 59000, Lille, France.
Jonathan MercierCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
Sylvain GerberInstitut de Systématique, Evolution, Biodiversité (ISYEB), Muséum National d'Histoire Naturelle, CNRS, SU, EPHE, UA, CP39, 57 Rue Cuvier, 75005, Paris, France.
Vincent MeyerCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
Anne BolandCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
Laurence BocketLaboratoire de Virologie ULR 3610, CHU Lille, University of Lille, 59000, Lille, France.
Robert OlasoCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France. olaso@cnrgh.fr.
Jean-François DeleuzeCEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France. deleuze@cnrgh.fr.
CEA Paris-Saclay · FRCentre National de Recherche en Génomique Humaine · FRGénétique Médicale & Génomique Fonctionelle · FRCentre Hospitalier Universitaire de Lille · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInstitut de Systématique, Évolution, Biodiversité · FRUniversité de Lille · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic caused by the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to threaten public health and burden healthcare systems worldwide. Whole SARS-CoV-2 genome sequencing has become essential for epidemiological monitoring and identification of new variants, which could represent a risk of increased transmissibility, virulence, or resistance to vaccines or treatment. Different next-generation sequencing approaches are used in SARS-CoV-2 sequencing, although with different ability to provide whole genome coverage without gaps and to reliably detect new variants. In this study, we compared the performance of three target enrichment methods (two multiplex amplification methods and one hybridization capture) using nasopharyngeal swabs from infected individuals. We applied these target enrichment methods to the same set of nasopharyngeal samples (N = 93) in high-throughput mode. SARS-CoV-2 genome was obtained using short-read next-generation sequencing. We observed that each method has some advantages, such as high mapping rate (CleanPlex and COVIDSeq) or absence of systematic variant calling error (SureSelect) as well as their limitations such as suboptimal uniformity of coverage (CleanPlex), high cost (SureSelect) or supply shortages (COVIDSeq). Nevertheless, each of the three target enrichment kits tested in this study yielded acceptable results of whole SARS-CoV-2 genome sequencing and either of them can therefore be used in prospective programs of genomic surveillance of SARS-CoV-2. Genomic surveillance will be crucial to overcoming the ongoing pandemic of COVID-19, despite its successive waves and continually emerging variants.

Indexed as

COVID-19SARS-CoV-2Genome, ViralHigh-Throughput Nucleotide SequencingHumansPandemicsProspective StudiesRNA, ViralRNA, Viral

Identifiers

PMID35869099
PMCPMC9306416
OpenAlexW4286560888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.